| Dr Spencer Pugh, MD | |
|
1924 Alcoa Hwy, Department Of Medicine U-114 Gsm, Utmck, Knoxville, TN 37920-1511 | |
| (865) 305-9340 | |
| (865) 305-9144 |
| Full Name | Dr Spencer Pugh |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 9 Years |
| Location | 1924 Alcoa Hwy, Knoxville, Tennessee |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003294992 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Parkwest Medical Center | Knoxville, TN | Hospital |
| Methodist Medical Center Of Oak Ridge | Oak ridge, TN | Hospital |
| Fort Loudoun Medical Center | Lenoir city, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Methodist Medical Center | 7012812860 | 10 |
| Parkwest Medical Center | 8527965417 | 55 |
| Statcare Inpatient Llc | 5496025074 | 103 |
| Statcare Outpatient Llc | 2264704055 | 32 |
News Archive
A University of Arkansas for Medical Sciences BioVentures startup company, InterveXion Therapeutics LLC, has received two federal grants totaling $14.5 million for development of drug therapies that can help methamphetamine drug abusers break their addiction.
The American Physical Society announces a new public access initiative that will give high school students and teachers in the United States full use of all online APS journals, from the most recent articles back to the first issue in 1893, a collection including over 400,000 scientific research papers.
Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company, today announced the introduction of Omeclamox-Pak®, a ten-day therapy of omeprazole delayed-release capsules (20 mg), clarithromycin tablets (500 mg) and amoxicillin capsules (500 mg) for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease (active or one-year history) to eradicate H. pylori in adult patients.
Emerging nanomedicine technologies could dramatically transform medical science as we know it today with their potential to address unmet medical needs and provide targeted therapy.
› Verified 4 days ago
| Entity Name | Parkwest Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396739165 PECOS PAC ID: 8527965417 Enrollment ID: O20040429000423 |
News Archive
A University of Arkansas for Medical Sciences BioVentures startup company, InterveXion Therapeutics LLC, has received two federal grants totaling $14.5 million for development of drug therapies that can help methamphetamine drug abusers break their addiction.
The American Physical Society announces a new public access initiative that will give high school students and teachers in the United States full use of all online APS journals, from the most recent articles back to the first issue in 1893, a collection including over 400,000 scientific research papers.
Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company, today announced the introduction of Omeclamox-Pak®, a ten-day therapy of omeprazole delayed-release capsules (20 mg), clarithromycin tablets (500 mg) and amoxicillin capsules (500 mg) for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease (active or one-year history) to eradicate H. pylori in adult patients.
Emerging nanomedicine technologies could dramatically transform medical science as we know it today with their potential to address unmet medical needs and provide targeted therapy.
› Verified 4 days ago
| Entity Name | Methodist Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700870672 PECOS PAC ID: 7012812860 Enrollment ID: O20050131000095 |
News Archive
A University of Arkansas for Medical Sciences BioVentures startup company, InterveXion Therapeutics LLC, has received two federal grants totaling $14.5 million for development of drug therapies that can help methamphetamine drug abusers break their addiction.
The American Physical Society announces a new public access initiative that will give high school students and teachers in the United States full use of all online APS journals, from the most recent articles back to the first issue in 1893, a collection including over 400,000 scientific research papers.
Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company, today announced the introduction of Omeclamox-Pak®, a ten-day therapy of omeprazole delayed-release capsules (20 mg), clarithromycin tablets (500 mg) and amoxicillin capsules (500 mg) for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease (active or one-year history) to eradicate H. pylori in adult patients.
Emerging nanomedicine technologies could dramatically transform medical science as we know it today with their potential to address unmet medical needs and provide targeted therapy.
› Verified 4 days ago
| Entity Name | Hospital Medicine Services Of Tennessee Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528433802 PECOS PAC ID: 9234432881 Enrollment ID: O20160114002673 |
News Archive
A University of Arkansas for Medical Sciences BioVentures startup company, InterveXion Therapeutics LLC, has received two federal grants totaling $14.5 million for development of drug therapies that can help methamphetamine drug abusers break their addiction.
The American Physical Society announces a new public access initiative that will give high school students and teachers in the United States full use of all online APS journals, from the most recent articles back to the first issue in 1893, a collection including over 400,000 scientific research papers.
Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company, today announced the introduction of Omeclamox-Pak®, a ten-day therapy of omeprazole delayed-release capsules (20 mg), clarithromycin tablets (500 mg) and amoxicillin capsules (500 mg) for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease (active or one-year history) to eradicate H. pylori in adult patients.
Emerging nanomedicine technologies could dramatically transform medical science as we know it today with their potential to address unmet medical needs and provide targeted therapy.
› Verified 4 days ago
| Entity Name | Statcare Inpatient Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477086981 PECOS PAC ID: 5496025074 Enrollment ID: O20170714002608 |
News Archive
A University of Arkansas for Medical Sciences BioVentures startup company, InterveXion Therapeutics LLC, has received two federal grants totaling $14.5 million for development of drug therapies that can help methamphetamine drug abusers break their addiction.
The American Physical Society announces a new public access initiative that will give high school students and teachers in the United States full use of all online APS journals, from the most recent articles back to the first issue in 1893, a collection including over 400,000 scientific research papers.
Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company, today announced the introduction of Omeclamox-Pak®, a ten-day therapy of omeprazole delayed-release capsules (20 mg), clarithromycin tablets (500 mg) and amoxicillin capsules (500 mg) for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease (active or one-year history) to eradicate H. pylori in adult patients.
Emerging nanomedicine technologies could dramatically transform medical science as we know it today with their potential to address unmet medical needs and provide targeted therapy.
› Verified 4 days ago
| Entity Name | Statcare Outpatient Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134653892 PECOS PAC ID: 2264704055 Enrollment ID: O20170814001441 |
News Archive
A University of Arkansas for Medical Sciences BioVentures startup company, InterveXion Therapeutics LLC, has received two federal grants totaling $14.5 million for development of drug therapies that can help methamphetamine drug abusers break their addiction.
The American Physical Society announces a new public access initiative that will give high school students and teachers in the United States full use of all online APS journals, from the most recent articles back to the first issue in 1893, a collection including over 400,000 scientific research papers.
Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company, today announced the introduction of Omeclamox-Pak®, a ten-day therapy of omeprazole delayed-release capsules (20 mg), clarithromycin tablets (500 mg) and amoxicillin capsules (500 mg) for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease (active or one-year history) to eradicate H. pylori in adult patients.
Emerging nanomedicine technologies could dramatically transform medical science as we know it today with their potential to address unmet medical needs and provide targeted therapy.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Spencer Pugh, MD 1924 Alcoa Hwy, Department Of Medicine U-114 Gsm, Utmck, Knoxville, TN 37920-1511 Ph: (865) 305-9340 | Dr Spencer Pugh, MD 1924 Alcoa Hwy, Department Of Medicine U-114 Gsm, Utmck, Knoxville, TN 37920-1511 Ph: (865) 305-9340 |
News Archive
A University of Arkansas for Medical Sciences BioVentures startup company, InterveXion Therapeutics LLC, has received two federal grants totaling $14.5 million for development of drug therapies that can help methamphetamine drug abusers break their addiction.
The American Physical Society announces a new public access initiative that will give high school students and teachers in the United States full use of all online APS journals, from the most recent articles back to the first issue in 1893, a collection including over 400,000 scientific research papers.
Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company, today announced the introduction of Omeclamox-Pak®, a ten-day therapy of omeprazole delayed-release capsules (20 mg), clarithromycin tablets (500 mg) and amoxicillin capsules (500 mg) for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease (active or one-year history) to eradicate H. pylori in adult patients.
Emerging nanomedicine technologies could dramatically transform medical science as we know it today with their potential to address unmet medical needs and provide targeted therapy.
› Verified 4 days ago
Corey Cudzilo, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2240 Sutherland Ave, Suite 103, Knoxville, TN 37919 Phone: 865-588-8831 Fax: 865-588-8841 | |
Dr. Joshua Weber Todd, M.D. Pulmonary Disease Medicare: May Accept Medicare Assignments Practice Location: 1819 W Clinch Ave, Suite 108, Knoxville, TN 37916 Phone: 865-546-5111 Fax: 865-541-4018 | |
Rasmi Ajit, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 9330 Park West Blvd Ste 402, Knoxville, TN 37923 Phone: 865-690-3003 Fax: 865-374-2143 | |
Saji Eapen, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1415 Old Weisgarber Rd, Suite 200, Knoxville, TN 37909 Phone: 865-934-5800 Fax: 865-934-5801 | |
Jeffrey W Robinson, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 6600 Nightingale Ln, Knoxville, TN 37909 Phone: 865-632-5885 | |
Dr. Mark D Anderson, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1928 Alcoa Hwy, B100, Knoxville, TN 37920 Phone: 865-544-6570 Fax: 865-544-6576 |